PTAB Won't Sanction Bass For AIA Reviews Of Drug Patents
The Patent Trial and Appeal Board refused Friday to sanction hedge fund manager Kyle Bass at the request of Celgene Corp. after the company argued that Bass is abusing the inter...To view the full article, register now.
Already a subscriber? Click here to view full article